Novavax Inc (NVAX)

[chrismiss_everyday]

Disruptive Technology

Kiss those egg-based vaccines goodbye.

Key findings of the Phase 2 clinical trial:

All formulations of NanoFlu were well-tolerated and elicited vigorous immune responses to the four strains included in the vaccine.

Matrix-M adjuvant resulted in significant enhancement of immune responses when compared to the unadjuvanted formulation.

NanoFlu is a differentiated flu vaccine, as evidenced by significantly superior hemagglutination inhibition (HAI) antibody responses against wild-type A(H3N2) viruses, including drifted strains, when compared to Fluzone High-Dose, the leading flu vaccine in older adults.

45% increase against vaccine-homologous virus, A/Singapore (p<0.001)

22% increase against a historic drifted virus, A/Switzerland (p=0.014)

42% increase against a forward drifted virus, A/Wisconsin (p<0.001)

NanoFlu formulation identified for the Phase 3 clinical trial and commercialization.